Alpha Tau Medical (DRTS) Stock Price, News & Analysis

Company Overview

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors. Alpha DaRT implants release alpha-emitting atoms that diffuse a few millimeters into the tumor, providing localized radiation doses that have shown promising preclinical and early clinical anti‐tumor activity. Alpha Tau Medical has secured Breakthrough Device designation from the U.S. Food and Drug Administration for certain cancer types and is advancing its pipeline through multi‐center trials in Europe and Israel.

Alpha Tau Medical collaborates with major oncology centers and academic institutions to conduct its clinical programs and to explore combination approaches with immunotherapies and other treatment modalities. The company has expanded its operational footprint beyond Israel, engaging regulatory and commercial partners in Europe while preparing for potential U.S. market entry. Through its focused R&D efforts and strategic alliances, Alpha Tau Medical seeks to establish alpha‐particle brachytherapy as a new standard of care for patients with challenging solid tumors.

Key Stats

• Today's Range: $3.80 to $4.12
• 50-Day Range: $2.90 to $4.09
• 52-Week Range: $2.11 to $4.39
• Volume: 79,173 shs
• Average Volume: 63,957 shs
• Market Capitalization: $346.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Alpha Tau Medical Stock Analysis - MarketRank™

Alpha Tau Medical scored higher than 32% of companies evaluated by MarketBeat, and ranked 772nd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Alpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Alpha Tau Medical has a consensus price target of $9.00, representing about 120.0% upside from its current price of $4.09.

Amount of Analyst Coverage

Alpha Tau Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.45) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Tau Medical is -8.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Tau Medical is -8.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Tau Medical has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.18% of the float of Alpha Tau Medical has been sold short.

Short Interest Ratio / Days to Cover

Alpha Tau Medical has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alpha Tau Medical has recently increased by 17.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Tau Medical does not currently pay a dividend.

Dividend Growth

Alpha Tau Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.18% of the float of Alpha Tau Medical has been sold short.

Short Interest Ratio / Days to Cover

Alpha Tau Medical has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alpha Tau Medical has recently increased by 17.85%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Alpha Tau Medical this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.65% of the stock of Alpha Tau Medical is held by institutions.

DRTS Stock Analysis - Frequently Asked Questions

How have DRTS shares performed this year?

Alpha Tau Medical's stock was trading at $3.10 at the start of the year. Since then, DRTS shares have increased by 31.9% and is now trading at $4.09.

How were Alpha Tau Medical's earnings last quarter?

Alpha Tau Medical Ltd. (NASDAQ:DRTS) released its quarterly earnings results on Monday, August, 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01.

Who are Alpha Tau Medical's major shareholders?

Alpha Tau Medical's top institutional investors include Levin Capital Strategies L.P. (0.23%).

How do I buy shares of Alpha Tau Medical?

Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alpha Tau Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpha Tau Medical investors own include Datadog (DDOG), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), PayPal (PYPL), Sunrun (RUN) and ZIM Integrated Shipping Services (ZIM).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/20/2025
• Next Earnings (Estimated): 11/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:DRTS
• CIK: 1871321
• Web: healthcarecapitalcorp.com
• Phone: 972-3577-4115
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alpha Tau Medical: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +120.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.21%
• Return on Assets: -38.18%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 10.52
• Quick Ratio: 5.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.89 per share
• Price / Book: 4.60

Miscellaneous

• Outstanding Shares: 84,820,000
• Free Float: 51,316,000
• Market Cap: $346.91 million
• Optionable: No Data
• Beta: 1.00